Latanoprost bunod

Edited by:

Menu

Summary of Evidence

Latanoprost bunod vs Timolol

At all 9 time points (IOP was measured at 8 am, 12 pm, and 4 pm of each follow-up visit ), the mean IOP in the study eye was significantly lower in the LBN 0.024% group than in the timolol 0.5% group.(APOLLO, 2016) {Weinreb RN, Scassellati Sforzolini B, Vittitow J, Liebmann J. Latanoprostene Bunod 0.024% versus Timolol Maleate 0.5% in Subjects with Open-Angle Glaucoma or Ocular Hypertension: The APOLLO Study. Ophthalmology. 2016 May;123(5):965-73.}

 

Mean IOP reduction in the LBN group was significantly greater than timolol at all but the first time point in this study (week 2, 8 AM).(LUNAR, 2016) {Medeiros FA, Martin KR, Peace J, Scassellati Sforzolini B, Vittitow JL, Weinreb RN. Comparison of Latanoprostene Bunod 0.024% and Timolol Maleate 0.5% in Open-Angle Glaucoma or Ocular Hypertension: The LUNAR Study. Am J Ophthalmol. 2016 Aug;168:250-259.}

Evidence

1. Background

2. Safety and efficacy

2.1 Comparative effectiveness

2.1.1 Latanoprostene bunod vs timolol

Clinical Trial

2016 Weinreb et.al. (APOLLO)

Article link | Archive link | Metrics cited by count

2016
Clinical Trial

At all 9 time points (IOP was measured at 8 am, 12 pm, and 4 pm of each follow-up visit ), the mean IOP in the study eye was significantly lower in the LBN 0.024% group than in the timolol 0.5% group. {Weinreb RN, Scassellati Sforzolini B, Vittitow J, Liebmann J. Latanoprostene Bunod 0.024% versus Timolol Maleate 0.5% in Subjects with Open-Angle Glaucoma or Ocular Hypertension: The APOLLO Study. Ophthalmology. 2016 May;123(5):965-73.}

  • Randomized controlled trial of Latanoprostene bunod ophthalmic solution 0.024% vs timolol 0.5% in patients with bilateral open angle glaucoma or ocular hypertension (387 patients)
Outcomes LBN 0.024% Timolol 0.5%
Proportion of subjects with mean IOP ≤18 mmHg 22.9% 11.3%
Proportion of subjects with IOP reduction ≥25% 34.9% 19.5%
cited by count
Clinical Trial

2016 Medeiros et.al. (LUNAR)

Article link | Archive link | Metrics cited by count

2016
Clinical Trial

Mean IOP reduction in the LBN group was significantly greater than timolol at all but the first time point in this study (week 2, 8 AM). {Medeiros FA, Martin KR, Peace J, Scassellati Sforzolini B, Vittitow JL, Weinreb RN. Comparison of Latanoprostene Bunod 0.024% and Timolol Maleate 0.5% in Open-Angle Glaucoma or Ocular Hypertension: The LUNAR Study. Am J Ophthalmol. 2016 Aug;168:250-259.}

  • Randomized controlled trial of Latanoprostene bunod ophthalmic solution 0.024% vs timolol 0.5% in patients with bilateral open angle glaucoma or ocular hypertension (387 patients)
Outcomes LBN 0.024% Timolol 0.5%
Proportion of subjects with mean IOP ≤18 mmHg 17.1% 11.1%
Proportion of subjects with IOP reduction ≥25% 31.0% 18.5%
cited by count

References

Comments

Subscribe
Notify of
guest
0 Comments
Inline Feedbacks
View all comments